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E-mail address: g.siegal@chem.leidenuniv.nl (G. SiThe Eph family of receptor tyrosine kinases regulates diverse cellular processes while the over-
expression of a member of this family, EphA4, has been reported in a variety of malignant carcino-
mas. To gain insight into molecular mechanisms and to facilitate structure-based inhibitor design,
we solved the crystal structure of the native EphA4 kinase domain in both the apo and dasatinib
bound forms. Analysis of the two structures provides insight into structural features of inhibitor
binding and revealed a hydrophobic back-pocket in the ATP- binding site of EphA4 which was pre-
viously unidentiﬁed. The structures suggest a route towards development of novel and speciﬁc
inhibitors.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The erythropoietin-producing hepatocellular (Eph) family of
receptor tyrosine kinases are key regulators of diverse cellular
functions including cell proliferation, differentiation and migration
[1]. In addition to the roles that kinases are traditionally associated
with such as mitogenesis, Eph receptors are also key factors in pro-
cesses such as axon growth and angiogenesis [2,3]. To date four-
teen different human Eph receptors and eight different ligands,
known as ephrins, have been identiﬁed [4]. The ephrins are divided
into two subclasses A and B, based on their GPI-anchored or trans-
membrane structure, respectively. The receptors are also classiﬁed
into two families, EphA and EphB, depending on the binding afﬁn-
ity for either the A or B ephrins, respectively [5]. The most well
known exception to this general rule is EphA4, which binds both
A- and B-class ligands [6–8].
In addition to its normal role in cellular regulation, over
expression of EphA4 has been observed in a variety of malignant
carcinomas including gastric cancer [9], prostate cancer [10] andchemical Societies. Published by E
brane segment; RTKs, recep-
egal).cutaneous lymphomas [11] among others. Furthermore, the over-
expressionof EphA4 seems tobe critical for tumorgrowth in a signif-
icant percentage of prostate cancers [10]. In addition to its potential
role in oncology, data obtained from EphA4-knockout mice suggest
that blocking EphA4 function might be beneﬁcial for the treatment
of spinal cord injuries [12]. The ability to modulate the activity of
this family of receptors could prove useful and therefore they repre-
sent interesting therapeutic targets.
Eph receptors share a common topology where the extracellular
region consists of: an N-terminal ephrin binding domain, a cys-
teine-rich region and two ﬁbronectin type III repeats near the sin-
gle membrane-spanning segment. The cytoplasmic region contains
a short amino acid sequence referred to as the juxtamembrane seg-
ment (JMS), the highly conserved tyrosine kinase domain (KD), a C
terminal sterile a domain (SAM) and a PDZ domain binding motif
[13]. The JMS domain contains tyrosine residues that must be
phosphorylated to allow full activation of the kinase activity [14]
which is unique to the Eph receptors. In the crystal structure of
EphB2, the JMS forms an a-helix that interacts with the kinase
domain and prevents it from adopting an ordered, active structure,
thus providing another level of regulation [15]. NMR studies of
EphB2 have shown that upon activating phosphorylation events,
the JMS and KD undergo increased conformational exchange [16].
It was postulated that autoinhibition was achieved via the JMSlsevier B.V. All rights reserved.
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conformation. Thus the additional regulatory switch represented
by the JMS could potentially also be a target for inhibitor design.
Dasatinib is a well known kinase inhibitor that was approved
for use in cases of imatinib resistance in chronic myeloid leukemia
(CML) [17]. Although dasatinib was primarily designed as a selec-
tive inhibitor of the Src and BCR-Abl kinases [18], it was found to
have a broader inhibition spectrum which includes members of
the Eph family [19,20]. However, no crystal structure of dasatinib
in complex with a member of this family has thus far been eluci-
dated. Since no structure of the wild type kinase domain was avail-
able, we wished to gain insight into the active form and to facilitate
structure-based inhibitor design by determining the crystal struc-
ture of the EphA4 kinase domain in both the apo and dasatinib
bound forms.
2. Materials and methods
2.1. Plasmid construction
The murine EphA4 kinase domain (amino acids 606–846) was
commercially synthesized with codon usage optimized for expres-
sion in Escherichia coli. The gene was cloned into a pET28a vector
(Invitrogen) generating an N-terminal 6His tag fused to the kinase
domain with an intervening region containing an amino acid
sequence efﬁciently hydrolyzed by the tobacco etch virus (TEV)
protease. The puriﬁed protein contained a single non-coded glycine
at the N terminus after cleavage.
2.2. Expression and puriﬁcation of EphA4 kinase domain
The details of expression and puriﬁcation of the EphA4 kinase
domain can be found in Supplementary material.
2.3. Crystallization of the EphA4 kinase domain
Crystals were grown at 20 C using the sitting-drop vapor-diffu-
sion method. The puriﬁed EphA4 kinase domain was mixed with
an equal volume of a reservoir solution containing 15–21% poly-
ethylene glycol 10 K, 100 mM ammonium acetate and 100 mM
bis–tris pH 5.5. Rod-like crystals appeared after 1–3 days.




boxamide) [21] was added to the puriﬁed protein at a ﬁnal
concentration of 1 mM in dimethyl sulfoxide (molar ratio dasatinib/
protein of 3) andmixed with an equal volume of a reservoir solution
containing 15–21% polyethylene glycol 10 K, 100 mM ammonium
acetate and100 mMbis–tris pH5.5. Crystals appeared after 1–3 days.
2.5. X-ray data collection, structure determination and reﬁnement
Crystals were ﬂash frozen using the reservoir solution supple-
mented with 20% glycerol as a cryoprotectant. Diffraction data for
the apo protein was collected at the Swiss Light Source (SLS, beam-
line X06SA) and at the European Synchrotron Radiation Facilities
(ESRF, beamline ID23-2) for the inhibitor bound. Datasets at 1.5 Å
for the apo-protein and 1.55 Å for the inhibitor complex were pro-
cessed using XDS [22] and POINTLESS [23] from the CCP4i suite
[24]. The apo-structure was solved bymolecular replacement using
the program AMoRe [25]. A mutant of EphA4 was used as a search
model (PDB ID: 2HEL). From the AMoRe solution, a model was builtand input into ARP/wARP [26] for automated tracing. The dasatinib-
bound structure was solved by molecular replacement (AMoRe)
using the native protein as a search model. The structures were re-
ﬁned using rigid body reﬁnement within the program REFMAC5
[27]. This was followed by restrained reﬁnement with PHENIX
[28] interspersed with rounds of model building with COOT [29].
A summary of the data collection and reﬁnements statistics is pre-
sented in Supplementary Table S1.
3. Results and discussion
3.1. Apo enzyme structure
The phosphorylated kinase domain of murine EphA4 (residues
606–846, referred to as EphA4 KD) was crystallized in the apo form
and the structure was determined at 1.7 Å resolution. The crystal-
lographic model contains one molecule in the asymmetric unit and
was reﬁned to an Rwork = 17.49% and Rfree = 20.32%. The overall bi-
lobed structure typical of kinases is well ordered except for three
N-terminal residues and ﬁve C-terminal residues and residues
765–787 of the activation segment. The N-terminal lobe consists
of the characteristic ﬁve-stranded b sheet and a single large a helix
(aC) while the C-terminal lobe is larger and mainly a-helical, but
includes a two stranded anti-parallel b-sheet as expected (Fig. 1).
Protein kinases contain a number of conserved elements that con-
tribute to the enzyme activity including: a hinge region connecting
the two lobes, a glycine rich loop or p-loop, a catalytic loop and an
activation loop, all of which are present in the EphA4 structures.
The activation loop includes a consensus Asp–Phe–Gly (DFG) motif
sequence that is critical for ATP binding [30] and is highly con-
served among kinases [31].
The present structure is characteristic of a phosphorylated, and
therefore activated, form of a kinase domain [32]. First, the aC-helix
is in the ATP proximal position allowing the formation of the con-
served Lys653–Glu670 salt bridge which coordinates the alpha and
beta phosphate groups of ATP via polar contacts. Second, the activa-
tion loop is disorganized and adopts the so-called ‘‘DFG-in’’ confor-
mation [33] with the side-chain of Phe765 pointing towards the
interior of the molecule (Fig. 1B).
3.2. Comparison of Eph receptor crystal structures
An EphA4 protein consisting of the kinase domain and the adja-
cent juxtamembrane segment (JMS), which comprises the muta-
tions Y596/602F in the JMS and Y742A in the KD, has been
previously crystallized (PDB ID: 2HEL) [16]. We refer to this struc-
ture as EphA4 JMS–KD. Although the resolution of this structure is
2.35 Å, the JMS is almost completely disordered. Overall, the struc-
tures of the two proteins are very similar with an r.m.s. deviation of
0.633 Å for the superimposition of 208 Ca atoms (Fig. 2A and Sup-
plementary Table S2). The C terminal lobe is nearly identical in the
two structures with the exception that ﬁve less amino acid residues
of the activation loop of EphA4 KD could be modeled. As the cata-
lytic and activation loops are spatially close to each other in the
EphA4 KD structure, the presence of the bulky side-chain of
Tyr742 in the catalytic loop leads to reduced interaction with the
activation loop and its subsequent disorganization. The Y742A
mutation in EphA4 JMS–KD removes the tyrosine side-chain allow-
ing repacking and stabilization of the activation loop. In contrast,
the N-terminal lobe shows greater differences between the KD
and JMS–KD structures. The largest difference observed is in the
location of the aC-helix where a 4.5 Å movement of the Ca of
Asp661 upward and outward in the KD structure causes the dis-
placement of the entire alpha helix. The aC-helix contains a kink
that leads to a bend of the long axis by 14 at about the midpoint
Fig. 1. Overview of the crystal structure of the EphA4 kinase domain. (A) Ribbon representation of the apo-EphA4 kinase domain crystal structure. The N-terminal lobe,
shown in pink, consists of a ﬁve-stranded anti-parallel b-sheet and one a-helix (aC). The C-terminal lobe, in grey, is mainly a-helical. The p-loop is colored orange, the hinge
region in green, the catalytic loop in blue and the activation loop in red. (B) Same as in A with a 90 rotation about the z axis. Residues important for kinase activation (Lys653,
Glu670 and Phe765) are shown in stick representation. All molecular graphics were generated with PyMOL (The PyMOL Molecular Graphics System; DeLano Scientiﬁc, 2002).
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the relative position of the alpha helix is different, which in turn
inﬂuences the position of the conserved Lys–Glu salt bridge. The
salt bridge is also inﬂuenced by the position of the p-loop which
is shifted upwards in the KD structure compared to the JMS–KD
structure. Thus, although the two crystals structures share an al-
most identical amino acid sequence, there are signiﬁcant structural
differences.
To try and determine whether the structural differences
between EphA4 KD and JMS–KD are related to the presence of
the JMS, we compared this pair to the structures of another KD
JMS–KD pair from the Eph family. Crystal structures of the closely
related kinase EphB2 have been solved both in the active state
(EphB2 KD, PDB ID: 2HEN) which comprise a D754A mutation in
the activation loop [16]) and the auto-inhibited state (EphB2
JMS–KD, PDB ID: 1JPA) [15]. In the EphB2 JMS–KD structure, a
Y604/610A mutation in the JMS has been made to prevent activa-
tion, which results in an enzyme with constitutively low activity
[14]. Overall, the structures of the two pairs of kinases are similar
except for the aC-helix and the p-loop which present slight
changes (Fig. 2B and Supplementary Table S2). The aC-helix exhib-
its a similar kink in all the structures, the cause of which was pre-
viously attributed to the JMS [15]. However, a subsequent crystal
structure of EphA2 was reported which also exhibited a bent con-
formation of the aC-helix despite the absence of a JMS (Fig. 2C)
[34]. The situation is similar with the present crystal structure of
EphA4 KD, i.e., a kink in the aC-helix even though the JMS is
absent. This observation conﬁrms the previous suggestion [16] that
the presence of the JMS in the EphA4 JMS–KD structure is not
responsible for the kink in the aC-helix. However, the relative
position of the aC-helix is different in all the structures (Fig. 2C).
In the present structure of active EphA4, the position of the aC-helix
is closer to the auto-inhibited JMS–KD of EphB2, indicating that the
details of the position of the aC-helix do not necessarily correlate
with the state of activity of the kinase.The variability of the p-loop in all four structures shown in
Fig. 2C, which inﬂuences the position of the conserved Lys–Glu salt
bridge, is even greater than the aC-helix. In the kinase domain of
EphA4, the position of the salt bridge is shifted, creating a larger
hydrophobic pocket than in the other Eph receptor kinases, includ-
ing speciﬁcally the EphA4 JMS–KD (Fig. 2D). Other Eph receptor
kinase domains that have been crystallized without the JMS or
mutations lack this hydrophobic pocket due to the position of the
salt bridge (Supplementary Fig. S1). In addition, it seems likely that
this pocket is present in the active, full-length kinase considering
inhibition of EphA4 by dasatinib has been demonstrated in the cell
[19] and dasatinib occupies this back pocket in our crystal structure
(see below). This newly discovered back-pocket should allow for
both enhanced speciﬁcity and potency for EphA4 inhibitors.
3.3. Structure of EphA4-dasatinib complex
Dasatinib is anATP competitive inhibitor that targetsmultiple ki-
nases. Amongst the numerous targets of dasatinib, it has been
shown to inhibit EphA4 [19,20]. Using a commercially available ki-
nase assay (ADP Hunter Plus, DiscoveRx), the IC50 of dasatinib for
the kinase domain of EphA4was 25 nM (data not shown). However,
no structural information regarding the binding of dasatinib to
EphA4 is available. In order to address this issue, dasatinib was co-
crystallized with EphA4 KD under conditions identical to the apo
protein. The structureof the complexwas solved to1.55 Å resolution
and reﬁned to an Rwork = 18.01% and Rfree = 20.05% (Fig. 3 and Sup-
plementary Table S1). Structural alignment of the apo and the dasat-
inib bound forms of EphA4 KD gives an r.m.s deviation of 0.150 Å
over 220 Ca atoms. Although the 3D structures are very similar,
the B factors of the apo and inhibitor bound proteins are subtly dif-
ferent (Fig. 4). B-factors are a measure of the order in the unit cell.
Careful inspection reveals that the backbone atoms have on average
slightly lower B-factors in the inhibitor bound complex while the
side-chains have somewhat larger B-factors. Dynamic behavior in
Fig. 2. Comparison of the EphA4 crystal structure with the kinase domain of other Eph receptor. (A) Superimposition of EphA4 structures: EphA4 KD (grey), EphA4 JMS–KD
(2HEL, red); Shown in bond representation: the residues contributing to the conserved salt bridge Lys–Glu and the Tyr/Ala residue in the activation loop (B) Superimposition
of EphA4 and EphB2 structures: EphA4 KD (grey), EphA4 JMS–KD (2HEL, red), EphB2 KD (2HEN, blue), EphB2 JMS–KD (1JPA, yellow). (C) Superimposition of EphA4, EphB2 and
EphA2: closer view of the N-lobe, the residues contributing to the conserved salt bridge Lys–Glu are shown in bond representation while the dots represent the van der Waal’s
surface of the salt bridge. EphA4 KD (grey), EphA4 JMS–KD (2HEL, red), EphB2 KD (2HEN, blue), EphB2 JMS–KD (1JPA, yellow), EphA2 KD (1MQB, green). (D) Close up view of
the ATP binding pocket of EphA4. The dots show the ATP binding pocket and the back hydrophobic pocket is circled in yellow. The orange, green, cyan and red elements
represent respectively the p-loop, hinge region, the salt bridge Lys653–Glu670 and the aC helix.
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pattern of dynamic changes on ligand binding (decreased dynamic
behavior of the backbone and increased dynamics of the side-
chains) has been observed in NMR [35]. The pattern of changes in
the B-factors suggests a thermodynamic explanation for binding,
i.e., that reduced entropy of the backbone in the dasatinib bound
form is compensated by increased entropy in the side-chains. As a
result, the net entropic change of ligand binding is minimal. The re-
duced B-factors for backbone atoms extends slightly further to-
wards the N-terminus in the dasatinib bound protein allowing two
additional amino acids to be modeled. As with the apo protein, the
aC-helix is in the ATP proximal position allowing the formation of
the conserved Lys653–Glu670 salt bridge indicative of the kinase ac-
tive state [32] while the activation loop is also in the ‘‘DFG-in’’ con-
formation [33].
Dasatinib makes several hydrogen bonds to the hinge and occu-
pies the hydrophobic pocket behind the Thr699 residue which is
commonly referred to as the ‘gatekeeper’ residue [36]. The side-
chain of the gatekeeper residue sterically controls inhibitor binding
to the hydrophobic pocket [37]. There are three main hydrogen
bonds between dasatinib and the kinase: one between the nitrogenof the amino-thiazole ring and the amidenitrogenofMet702, another
between the amino group of the amino-thiazole ring with the car-
bonyl oxygen of Met702 and a third one between the amide nitrogen
of dasatinib and the side-chain hydroxyl oxygen of Thr699. The 2-
chloro-6-methyl phenyl group of dasatinib occupies the hydropho-
bic pocket andmakes extensive van derWaal’s (vdW) contacts with
Lys653, Glu670, Met674, Ile683, Ile697 and Thr699. The amino-thiazole
ring has vdW’s contacts with Leu753 and Ala651, in addition to the
previously described hydrogen bond. The pyrimidine ring extends
out of the binding pocket and makes vdW contact with Ile627. The
hydroxyethyl-piperazine group is largely solvent exposed.
In an analysis of the Eph receptor family [20], it was observed
that, except for EphA6 and EphA7, dasatinib inhibited all of the
Eph receptors. Interestingly, the gatekeeper residue in EphA6 is
Val and Ile in EphA7, while in all other members of the family it
is Thr. The bulky gatekeeper residues in EphA6 and EphA7 likely
obstruct access to the hydrophobic pocket. The pattern of inhibi-
tion is not surprising since dasatinib was designed to access the
hydrophobic pocket created by the mutation of the gatekeeper
residue from Ile to Thr in Abl kinase that lead to resistance to
imatinib [17,18]. It seems likely that the mode of binding of
Fig. 3. Binding mode of dasatinib to EphA4. (A) Overview of the binding interaction. Dasatinib and residues that interact with it are shown in bond view, hydrogen bounds are
indicated by black dashed lines. (B) View of dasatinib overlaid with the simulated annealing omit-map F0–Fc electron density contoured at 2r.
Fig. 4. Average B factor per residue number. In black the values for main chain, and in red values for the side-chains. Solid lines are values for the apo-form and the dashed
lines are values for the dasatinib bound form.
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are inhibited by this compound.
3.4. Structural comparison with other kinases bound to dasatinib
Since a number of other dasatinib bound structures have been
elucidated, it is useful to compare the present structure to these.
We have selected four representative structures, two from the
Src family (Src [38], and Lyn [39]), the Ableson kinase (Abl [40])
and Bruton’s tyrosine kinase (BTK) [41]) for comparison with our
dasatinib-bound EphA4 structure. In all ﬁve structures, the
2-chloro-6-methyl phenyl group of dasatinib occupies a hydropho-
bic pocket adjacent to the ATP-binding site behind the gatekeeper
residue, which in all cases is a Thr (Fig. 5A). All 5 structures exhibitan aC-helix in the ATP-proximal position, the salt bridge between
Lys and Glu and an activation loop with the ‘‘DFG-in’’ conforma-
tion. The kink in the aC-helix is present in all the structures and
the position of the helix is slightly different in each (Fig. 5B). How-
ever, the salt bridge is in the same position in all the structures.
Although the binding mode of dasatinib is globally similar in all
the structures, two different binding orientations are observed
for the 2-chloro-6-methyl phenyl group of dasatinib. The chloride
is pointing toward the C-terminal lobe in the Src, Lyn and EphA4
complexes (Fig. 5C), while the chloro substituent is pointing in
the opposite direction in the Abl and BTK complexes (Fig. 5D).
However, it is not clear why the different binding orientations
are observed, it may be related to the resolution. In the present, rel-
atively high resolution EphA4 structure, the orientation of the
Fig. 5. (A) Sequence alignment of a portion of the EphA4 kinase domain with other RTKs that bind dasatinib: Lyn, BTR, c-Src and Abl. Variable residues are indicated in blue;
and the residues that interact with dasatinib are shown in red. The potency of dasatinib inhibition of each kinase is indicated on the right. (B) Superimposition of EphA4
(2Y6O, grey), Lyn (2ZVA, blue), c-Src (3G5D, magenta), BTK (3K54, yellow) and Abl (2GQG, red). The residues contributing to the conserved salt bridge are shown in bond
representation. (C) Superimposition of EphA4 (2Y6O, grey), Lyn (2ZVA, blue) and c-Src (3G5D, magenta). The residues contributing to the conserved salt bridge and the
gatekeeper residue (Thr) are shown in bond representation. (D) Superimposition of EphA4 (2Y6O, grey), BTK (3K54, yellow) and Abl (2GQG, red), in addition to the residues
contributing to the salt bridge and the gatekeeper residue (Thr), selected residues in the p-loop are shown in bond representation (Gly250 and Tyr253 for Abl, Gly411 for BTK and
Gly630 for EphA4).
3598 C. Farenc et al. / FEBS Letters 585 (2011) 3593–3599chloro substituent pointing toward the C-terminal lobe ﬁt the elec-
tron density better.
In addition to the hydrophobic pocket, differences are observed
in the p-loop in both Abl and BTK structures compared to EphA4.
There is a 7.7 Å movement of the Ca of Abl Gly250 towards the
ATP binding site in comparison to the corresponding EphA4
Gly630 (Fig. 5D). The p-loop of BTK shows a similar movement to
Abl, although to a slightly lesser extent, with a 3.65 Å movement
of the Ca of BTK Gly411 towards the ATP binding site in comparison
to the corresponding Gly630 of EphA4. Moreover, Abl Tyr253 makes
several vdW’s contacts with the amino thiazole of dasatinib that
are absent in the other complexes. The p-loop in BTK and Abl packs
closer to the core of the kinase as evidenced by the shorter distance
between the methyl substituent of the pyrimidine ring and the p-
loop of BTK (8.69 Å to Gly411) and Abl (7.12 Å to Gly250) in compar-
ison to EphA4 (9.85 Å to Gly630), thereby partially shielding dasat-
inib from solvent. The position of the p-loop may relate to the
differences in afﬁnity for dasatinib noted in Fig. 5A.
4. Conclusion
We have elucidated the structure of the native EphA4 kinase
domain and the ﬁrst structure of this domain in complex with an
inhibitor. The structure of the native kinase domain suggests that
the JMS in EphA4 is not responsible for the change in the relative po-
sition of the aC-helix as was previously suggested [16]. In addition,
the structure reveals a hydrophobic back-pocket in the ATP-bindingsite of EphA4 which was unknown before. The crystal structure of
EphA4 in complex with dasatinib revealed a binding mode closely
related to the one exhibited by Src family members, c-Src and Lyn.
Access to the hydrophobic pocket is governed by the gatekeeper
residue while the size of the pocket appears to be governed by the
position of the Lys–Glu salt bridge. The gatekeeper residue is con-
served among 12 of the 14 human Eph receptors while, in our
structure, the position of the conserved salt bridge is shifted, offer-
ing a larger hydrophobic pocket than in the other Eph receptors.
This unique combination of gatekeeper and position of the salt
bridge suggests a manner to design new, EphA4 speciﬁc inhibitors.
Further mutational experiments targeting the ATP binding site and
the hydrophobic pocket in particular could shed light on the poten-
tial to develop EphA4 speciﬁc compounds.
5. PDB accession numbers
Atomic coordinate and structure factors of apo- EphA4 and
dasatinib-EphA4 were deposited in the Protein Data Bank under
accession numbers 2Y6M and 2Y6O, respectively.
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